Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis

Recruiting N/A Interventional Study
Psychotic Episode
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
15 – 35
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
416 (estimated)
Sponsor
Centre Hospitalier Universitaire de Saint Etienne · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia. Numerous studies show that the rapidity of the initial management of FPE would reduce the risk of negative evolution and would have a decisive impact on the short and long term prognosis. The rapidity o…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder established according to DMS 5 * Never having taken neuroleptic treatment for antipsychotic purposes, except for the current episode and for a duration …
Contacts

Eric FAKRA, MD PhD

(0)477127885

eric.fakra@chu-st-etienne.fr

CONTACT

Amandine BAUDOT, CRA

(0)477829450

amandine.baudot@chu-st-etienne.fr

CONTACT